



ASX Company Announcement

21 October 2009

Renounceable Rights Issue

Sun Biomedical Limited (ASX:SBN) wishes to advise that the Company has today undertaken a renounceable rights issue.

The Rights Issue is on the basis of a one (1) New Share for every one (1) Share held by Shareholders registered at 7.00pm EST on 29 October 2009 at an issue price of \$0.001 per New Share to raise approximately \$891,456. Shareholders will also have the right to apply for additional New Shares under a Shortfall Facility.

The rights issue is fully underwritten by Patersons Securities Limited.

Please find **attached** Appendix 3B pertaining to the Rights Issue.

For further information regarding this announcement please contact:

Terry Cuthbertson
Chairman

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Name of entity

SUN BIOMEDICAL LIMITED

ABN

18 001 285 230

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- | | | |
|---|--|-----------------------------|
| 1 | +Class of +securities issued or to be issued | Ordinary shares. |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued | 891,456,280 |
| 3 | Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | Fully paid ordinary shares. |

+ See chapter 19 for defined terms.

| <p>4 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?</p> <p>If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</p> | <p>Yes. Ordinary Shares rank pari passu with fully paid ordinary shares on issue.</p> | | | | | | |
|--|---|-----------|--|---------------|--|-------------|---|
| <p>5 Issue price or consideration</p> | <p>0.1 cents per ordinary share.</p> | | | | | | |
| <p>6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p> | <p>The funds raised will be used for working capital to identify and assess potential growth opportunities and acquisitions.</p> | | | | | | |
| <p>7 Dates of entering +securities into uncertificated holdings or despatch of certificates</p> | <p>21 October 2009.</p> | | | | | | |
| <p>8 Number and +class of all +securities quoted on ASX (including the securities in clause 2 if applicable)</p> | <table border="1"> <thead> <tr> <th data-bbox="766 1288 1069 1355">Number</th> <th data-bbox="1069 1288 1361 1355"></th> </tr> </thead> <tbody> <tr> <td data-bbox="766 1355 1069 1411">1,782,912,560</td> <td data-bbox="1069 1355 1361 1411">Ordinary Shares</td> </tr> <tr> <td data-bbox="766 1411 1069 1523">186,950,659</td> <td data-bbox="1069 1411 1361 1523">Options exercisable at \$0.02, expiring 30 November 2010</td> </tr> </tbody> </table> | Number | | 1,782,912,560 | Ordinary Shares | 186,950,659 | Options exercisable at \$0.02, expiring 30 November 2010 |
| Number | | | | | | | |
| 1,782,912,560 | Ordinary Shares | | | | | | |
| 186,950,659 | Options exercisable at \$0.02, expiring 30 November 2010 | | | | | | |
| <p>9 Number and +class of all +securities not quoted on ASX (including the securities in clause 2 if applicable)</p> | <table border="1"> <tbody> <tr> <td data-bbox="766 1523 1069 1624">4,000,000</td> <td data-bbox="1069 1523 1361 1624">Options – exercise price 4.5 cents, expiring 31 Dec 2010.</td> </tr> <tr> <td data-bbox="766 1624 1069 1724">20,000,000</td> <td data-bbox="1069 1624 1361 1724">Options – exercise price 10 cents, expiring 30 June 2011.</td> </tr> <tr> <td data-bbox="766 1724 1069 1879">2,000,000</td> <td data-bbox="1069 1724 1361 1879">Options – exercise price 2 cents, expiring 15 Sept 2011.</td> </tr> </tbody> </table> | 4,000,000 | Options – exercise price 4.5 cents, expiring 31 Dec 2010. | 20,000,000 | Options – exercise price 10 cents, expiring 30 June 2011. | 2,000,000 | Options – exercise price 2 cents, expiring 15 Sept 2011. |
| 4,000,000 | Options – exercise price 4.5 cents, expiring 31 Dec 2010. | | | | | | |
| 20,000,000 | Options – exercise price 10 cents, expiring 30 June 2011. | | | | | | |
| 2,000,000 | Options – exercise price 2 cents, expiring 15 Sept 2011. | | | | | | |

+ See chapter 19 for defined terms.

- | | |
|--|---|
| <p>10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)</p> | <p>The directors of the Company may from time to time determine to distribute the profits of the Company by way of dividend amongst the Shareholders in proportion to the amounts paid up on the Shares held by them.</p> |
|--|---|

Part 2 - Bonus issue or pro rata issue

- | | |
|---|--|
| <p>11 Is security holder approval required?</p> | |
| <p>12 Is the issue renounceable or non-renounceable?</p> | |
| <p>13 Ratio in which the +securities will be offered</p> | |
| <p>14 +Class of +securities to which the offer relates</p> | |
| <p>15 +Record date to determine entitlements</p> | |
| <p>16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?</p> | |
| <p>17 Policy for deciding entitlements in relation to fractions</p> | |
| <p>18 Names of countries in which the entity has +security holders who will not be sent new issue documents</p> <p><small>Note: Security holders must be told how their entitlements are to be dealt with.</small></p> <p><small>Cross reference: rule 7.7.</small></p> | |
| <p>19 Closing date for receipt of acceptances or renunciations</p> | |
| <p>20 Names of any underwriters</p> | |
| <p>21 Amount of any underwriting fee or commission</p> | |
| <p>22 Names of any brokers to the issue</p> | |

+ See chapter 19 for defined terms.

| | | |
|----|---|--|
| 23 | Fee or commission payable to the broker to the issue | |
| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders | |
| 25 | If the issue is contingent on +security holders' approval, the date of the meeting | |
| 26 | Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled | |
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders | |
| 28 | Date rights trading will begin (if applicable) | |
| 29 | Date rights trading will end (if applicable) | |
| 30 | How do +security holders sell their entitlements <i>in full</i> through a broker? | |
| 31 | How do +security holders sell <i>part</i> of their entitlements through a broker and accept for the balance? | |
| 32 | How do +security holders dispose of their entitlements (except by sale through a broker)? | |
| 33 | +Despatch date | |

+ See chapter 19 for defined terms.

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of securities
(tick one)

(a) Securities described in Part 1

(b) All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36 If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over

37 A copy of any trust deed for the additional +securities

Entities that have ticked box 34(b)

38 Number of securities for which +quotation is sought

39 Class of +securities for which quotation is sought

+ See chapter 19 for defined terms.

40 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

If the additional securities do not rank equally, please state:
the date from which they do
the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

| |
|--|
| |
|--|

41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another security, clearly identify that other security)

| |
|--|
| |
|--|

42 Number and +class of all +securities quoted on ASX (*including* the securities in clause 38)

| Number | +Class |
|--------|--------|
| | |

+ See chapter 19 for defined terms.

Quotation agreement

- 1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
- 2 We warrant the following to ASX.
- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.
 - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.
- Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
 - If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.



Sign here: Date: 21 October 2009

Print name: Alfonso Grillo (Company secretary)